Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ANTHEM

ANTHEM

HealthcarePharmaceuticals & Biotechnology₹51484 cr market cap
₹936.80 ▲ +2.46% today As of 19 Nov 2026
52-week low ₹587.8552-week high ₹958.15

-4.6% from the 52-week high · +55.5% above the low

Anthem Biosciences Ltd operates in pharmaceutical and biotechnology research, manufacturing, and development. The company delivers innovative healthcare solutions and high-quality products, supporting medical research and patient care across various therapeutic areas.

The short version. ANTHEM reported revenue of ₹594 crore for Sep 2026, up 8.0% from a year earlier. Net profit was ₹211 crore (up 22.0% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 71.4% in Sep 2026, down 3.29 points over 6 quarters.

1 · The price

How has the stock traded?

ANTHEM trades 4.6% below its 52-week high and 55.5% above its 52-week low.

Change over period: —

1M+13.1%
3M+3.7%
6M+17.1%
1Y+38.6%

2 · The business

Is it growing?

Sales, year on year+8.0%

Sep 2026 revenue of ₹594 cr.

Profit, year on year+22.0%

Sep 2026 net profit of ₹211 cr.

Net margin35.6%

4.1 pts higher than a year earlier.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025
Revenue594418611423550540
Net profit21112019093173136
Net margin %35.628.731.121.931.525.1
EPS (₹)3.752.133.381.653.092.42

Annual

FY2026
Revenue2124
Net profit592
Net margin %27.9
EPS (₹)10.54

3 · The quality

How well does it turn capital into profit?

Return on equity was 19.4% in Mar 2026; debt to equity is 0.02.

Profitability · 1 years

Returns and margins

Mar 2026
Return on equity %19.4
Return on capital %26.8
EBITDA margin %42.3
Net margin %25.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR——
Profit CAGR——
Debt to equity0.02
Interest cover120.6x
Current ratio5.54
P/E ratio84.7

4 · The owners

Who holds it, and are they adding?

Promoter holding71.4%

Down 3.29 pts over 6 quarters.

Foreign institutions3.79%

Up 2.29 pts over 6 quarters.

Domestic institutions12.1%

Up 8.49 pts over 6 quarters.

Mutual fund schemes160

+39 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter74.6974.6974.6974.6871.4271.4-3.29
FII1.51.671.361.282.583.79+2.29
DII3.617.227.611.5513.4812.1+8.49
Public20.216.4216.3512.512.5312.7-7.5

Mutual fund holdings · Oct 2026

160 schemes hold this stock

121 the month before.

  • Motilal Oswal Manufacturing Fund3.97% of NAV
  • TATA INDIA PHARMA & HEALTHCARE FUND2.99% of NAV
  • HDFC Business Cycle Fund2.97% of NAV
  • SBI MNC Fund2.97% of NAV
  • HDFC Pharma and Healthcare Fund2.92% of NAV
  • Capitalmind Flexi Cap Fund2.67% of NAV
  • SBI Healthcare Opportunities Fund2.57% of NAV
  • Kotak Healthcare Fund2.17% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ANTHEM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ANTHEM

What is the ANTHEM share price?

ANTHEM (ANTHEM) last closed at ₹936.80, up 2.46% on the day. Its 52-week range is ₹587.85 to ₹958.15.

What is the market cap of ANTHEM?

ANTHEM has a market capitalisation of about ₹51,484 crore. Its price-to-earnings ratio is 84.7.

How are ANTHEM's latest results?

ANTHEM reported revenue of ₹594 crore for Sep 2026, up 8.0% from a year earlier. Net profit was ₹211 crore (up 22.0% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 71.4% in Sep 2026, down 3.29 points over 6 quarters.

Who owns ANTHEM?

As of Sep 2026, shareholding was: Promoter 71.4%, FII 3.79%, DII 12.1%, Public 12.7%.

How many mutual funds hold ANTHEM?

160 mutual fund schemes held ANTHEM in October 2026. That compares with 121 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 25 Jun 2026 · Final Dividend - Rs. 2

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.